Shot in the arm for generics, say oncologists

The Supreme Court’s decision to deny Novartis a fresh patent for its anti-leukaemia drug, Glivec/Imatinib, has been hailed as a move that will bring life to generics. Medical oncologists fete it for another reason: If the judgment had gone any other way, the existing generics in the market would have to disappear.

Read Full Story>>